|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we found that monoclonal antibodies derived from humans vaccinated with the HVEM binding domain of HSV-1 gD (i) neutralized HSV-1 infection in a cell receptor-specific manner, (ii) mediated ADCC, and (iii) reduced ocular disease in virus-infected mice.<b>IMPORTANCE</b> Herpes simplex virus 1 (HSV-1) causes cold sores and neonatal herpes and is a leading cause of blindness.
|
28701403 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
A role for herpesvirus entry mediator as the receptor for herpes simplex virus 1 entry into primary human trabecular meshwork cells.
|
16189018 |
2005 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus (HSV) entry into cells is triggered by the binding of envelope glycoprotein D (gD) to a specific receptor, such as nectin-1 or herpesvirus entry mediator (HVEM), resulting in activation of the fusion effectors gB and gH and virus penetration.
|
20861246 |
2010 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine cellular and temporal expression patterns of herpes virus entry mediator (HVEM, Tnfrsf14) in the murine cornea during the course of herpes simplex virus 1 (HSV-1) infection, the impact of this expression on pathogenesis, and whether alterations in HVEM or downstream HVEM-mediated effects ameliorate corneal disease.
|
28114589 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review the dual branches of HVEM function during HSV infection: entry and immunomodulation.
|
28404853 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, we reported that the herpesvirus entry mediator (HVEM; also called TNFRSF14 or CD270) is upregulated by the latency-associated transcript (LAT) of herpes simplex virus 1 (HSV-1) and that the absence of HVEM affects latency reactivation but not primary infection in ocularly infected mice. gD has been shown to bind to HVEM.
|
30282707 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
|
27693350 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HVEM and its ligands have been involved in the pathogenesis of various autoimmune, inflammatory diseases and tumors.
|
23976978 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of HVEM was not associated with age, gender, administration of preoperative chemotherapy, tumor size, number of tumors, or histologic differentiation.
|
31313042 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we have shown that adenovirus-expressing TNFSF14 [LIGHT (name derived from homologous to lymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes); Ad-LIGHT] inoculated directly into primary 4T1 tumor, a highly aggressive, spontaneously metastasizing mammary carcinoma, followed by surgical removal of the primary tumor can eradicate established and disseminated metastatic tumor cells in the peripheral tissues.
|
17641063 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, the role of HVEM within diverse cancers and in regulating the immune responses to these tumors is likely context specific.
|
30885361 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of LIGHT (LIGHT: homologous to lymphotoxins, indicating inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator [HVEM/TR2]) in MDA-MB-231 human breast cancer cells was observed to suppress tumor growth in vivo.
|
12651068 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HVEM is constitutively expressed on the surface of tumor B cells.
|
14562115 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In eight cases (42%) we observed recurrent copy number loss of chr1:2,352,236-4,574,271, a region containing the candidate tumor suppressor TNFRSF14.
|
26650888 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, TNFRSF14 may serve a tumor suppressive role in bladder cancer by inducing apoptosis and suppressing proliferation, and act as a novel prognostic biomarker for bladder cancer.
|
30066919 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, Cav3.2 inhibition decreased expression of oncogenes (PDGFA, PDGFB, and TGFB1) and increased expression of tumor suppressor genes (TNFRSF14 and HSD17B14).
|
28512247 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LIGHT (Lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells) is a ligand that induces robust anti-tumor immunity by enhancing the recruitment and activation of effector immune cells at tumor sites.
|
28423548 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Univariate analysis revealed that the high expression of BTLA and HVEM was associated with overall survival of patients along with tumor size, Borrmann type, depth of invasion, lymph node metastasis, and histological grade (<i>P</i><0.05).
|
28243127 |
2017 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
TNFRSF14 is known as herpes virus entry mediator (HVEM), and herpes viruses have been involved in the aetiology of multiple sclerosis (MS).
|
20962851 |
2011 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Herpes virus entry mediator (HVEM) is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF14), which serves as a receptor for herpes viruses and cytokines such as lymphotoxin-alpha (LT-alpha) and LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells).
|
19680232 |
2010 |
|
Herpes NOS
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
To determine cellular and temporal expression patterns of herpes virus entry mediator (HVEM, Tnfrsf14) in the murine cornea during the course of herpes simplex virus 1 (HSV-1) infection, the impact of this expression on pathogenesis, and whether alterations in HVEM or downstream HVEM-mediated effects ameliorate corneal disease.
|
28114589 |
2017 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Overexpression of LIGHT (LIGHT: homologous to lymphotoxins, indicating inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator [HVEM/TR2]) in MDA-MB-231 human breast cancer cells was observed to suppress tumor growth in vivo.
|
12651068 |
2003 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity.
|
21877247 |
2012 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Characterization of Sex Differences in Ocular Herpes Simplex Virus 1 Infection and Herpes Stromal Keratitis Pathogenesis of Wild-Type and Herpesvirus Entry Mediator Knockout Mice.
|
30918059 |
2019 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
One such gene, tumor necrosis factor receptor superfamily 14 (TNFRSF14), abnormal in 40% of FL patients, encodes the herpes virus entry mediator (HVEM) which limits T-cell activation via ligation of the B- and T-lymphocyte attenuator.
|
27103745 |
2016 |